SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI

por Sattar, Abdul, Thommes, Pia, Payne, Lloyd, Warn, Peter, Vickers, Richard J.
Publicado en J Antimicrob Chemother (2015)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin

por Thorpe, Cheleste M., Kane, Anne V., Chang, Justin, Tai, Albert, Vickers, Richard J., Snydman, David R.
Publicado en PLoS One (2018)

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile

por Collins, Deirdre A, Wu, Yuan, Tateda, Kazuhiro, Kim, Hee-Jung, Vickers, Richard J, Riley, Thomas V
Publicado en J Antimicrob Chemother (2020)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

por Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Publicado en J Antimicrob Chemother (2016)

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

por Snydman, David R, McDermott, Laura A, Thorpe, Cheleste M, Chang, Justin, Wick, Jenna, Walk, Seth T, Vickers, Richard J
Publicado en J Antimicrob Chemother (2018)

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

por Qian, Xi, Yanagi, Karin, Kane, Anne V., Alden, Nicholas, Lei, Ming, Snydman, David R., Vickers, Richard J., Lee, Kyongbum, Thorpe, Cheleste M.
Publicado en Am J Physiol Gastrointest Liver Physiol (2020)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-infer...

por Vickers, Richard J, Tillotson, Glenn S, Nathan, Richard, Hazan, Sabine, Pullman, John, Lucasti, Christopher, Deck, Kenneth, Yacyshyn, Bruce, Maliakkal, Benedict, Pesant, Yves, Tejura, Bina, Roblin, David, Gerding, Dale N, Wilcox, Mark H
Publicado en Lancet Infect Dis (2017)

Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars

por Westwood, Isaac M., Bhakta, Sanjib, Russell, Angela J., Fullam, Elizabeth, Anderton, Matthew C., Kawamura, Akane, Mulvaney, Andrew W., Vickers, Richard J., Bhowruth, Veemal, Besra, Gurdyal S., Lalvani, Ajit, Davies, Stephen G., Sim, Edith
Publicado en Protein Cell (2010)